Dartmouth Health Continuing Education for Professionals Home, AXL: Advanced Opioid Use Disorder X-waiver Team Learning Collaborative: Managing Injection Behaviors: The Partial Responder to MAT, 9/1/2021 8:00:00 AM - 9/1/2024 9:00:00 AM, This series is designed to increase treatment capacity for opioid use disorders by training more prescribers to be able to treat substance or opioid use disorders.
Content includes:
• Assessing drivers of ongoing drug use among patients receiving MOUD, including buprenorphine misuse
• Improving outcome by connection with comprehensive treatment and recovery supports
• Use of behavioral, pharmacologic and care management strategies for identifying and responding to continued symptoms of OUD
Presenter
• Dr. Stoller is on faculty in the Department of Psychiatry and Behavioral Sciences at the Johns Hopkins University School of Medicine, and a well-regarded expert on substance use disorders, including opioid addiction. He has developed, evaluated and disseminated models of care geared toward multi-morbid populations that are integrative and promote adherence. His most impactful focus has been on collaborative care models, treatment access, program building, health policy, and healthcare utilization/cost. He developed and disseminated a collaborative opioid prescribing (“CoOP”) model which has received high level attention from SAMHSA, ONDCP, and professional societies, and has been instituted by programs and localities nationwide. Dr. Stoller is deeply-engaged with local, state and national associations and governmental agencies engaged in addressing the opioid epidemic. He directs the Johns Hopkins Hospital’s outpatient addiction treatment program, and serves as the Medical Director for Behavioral Health at Johns Hopkins HealthCare, which provides health care services for four health plans.
Learning Outcome(s)
Participants will be able to identify at least three evidence-based strategies that are designed to enhance the clinical team-based care of patients with substance or opioid use disorders treatment.
Disclosure
The activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for this activity have reported NO financial relationship(s)* with ineligible companies**.
* A “financial relationship" includes employee, researcher (named as the PI), consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and/or an ownership interest (not including stocks owned in a managed portfolio).
** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Bibliographic Resources
• Kidorf M, Disney ER, King VL, Neufeld K, Beilenson PL, Brooner RK. Prevalence of psychiatric and substance use disorders in opioid abusers in a community syringe exchange program. Drug Alcohol Depend. 2004 May 10;74(2):115-22.
• Clark MR, Stoller KB, Brooner RK. Assessment and management of chronic pain in individuals seeking treatment for opioid dependence disorder. Can J Psychiatry. 2008 Aug;53(8):496-508.
• Rosenblum A, Joseph H, Fong C, Kipnis S, Cleland C, Portenoy RK. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA. 2003 May 14;289(18):2370-8.
• Peles E, Schreiber S, Gordon J, Adelson M. Significantly higher methadone dose for methadone maintenance treatment (MMT) patients with chronic pain. Pain. 2005 Feb;113(3):340-346.
• Potter JS, Shiffman SJ, Weiss RD. Chronic pain severity in opioid-dependent patients. Am J Drug Alcohol Abuse. 2008;34(1):101-7.
• Sheu R, Lussier D, Rosenblum A, Fong C, Portenoy J, Joseph H, Portenoy RK. Prevalence and characteristics of chronic pain in patients admitted to an outpatient drug and alcohol treatment program. Pain Med. 2008 Oct;9(7):911-7.
• Harm Reduction Coalition website. Set of principles at: https://harmreduction.org/about-us/principles-of-harm-reduction/
• Providers Clinical Support System (SAMHSA-funded program): https://pcssnow.org/mentoring/
• Federal Guidelines for Opioid Treatment Programs: http://store.samhsa.gov/product/Federal-Guidelines-for-Opioid-Treatment- Programs/PEP15-FEDGUIDEOTP
• SAMHSA TIP 63: Medications for Opioid Use Disorder: https://store.samhsa.gov/product/TIP-63-Medications-for-Opioid-Use- Disorder-Full-Document/PEP21-02-01-002
Content includes:
• Assessing drivers of ongoing drug use among patients receiving MOUD, including buprenorphine misuse
• Improving outcome by connection with comprehensive treatment and recovery supports
• Use of behavioral, pharmacologic and care management strategies for identifying and responding to continued symptoms of OUD
Presenter
• Dr. Stoller is on faculty in the Department of Psychiatry and Behavioral Sciences at the Johns Hopkins University School of Medicine, and a well-regarded expert on substance use disorders, including opioid addiction. He has developed, evaluated and disseminated models of care geared toward multi-morbid populations that are integrative and promote adherence. His most impactful focus has been on collaborative care models, treatment access, program building, health policy, and healthcare utilization/cost. He developed and disseminated a collaborative opioid prescribing (“CoOP”) model which has received high level attention from SAMHSA, ONDCP, and professional societies, and has been instituted by programs and localities nationwide. Dr. Stoller is deeply-engaged with local, state and national associations and governmental agencies engaged in addressing the opioid epidemic. He directs the Johns Hopkins Hospital’s outpatient addiction treatment program, and serves as the Medical Director for Behavioral Health at Johns Hopkins HealthCare, which provides health care services for four health plans.
Learning Outcome(s)
Participants will be able to identify at least three evidence-based strategies that are designed to enhance the clinical team-based care of patients with substance or opioid use disorders treatment.
Disclosure
The activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for this activity have reported NO financial relationship(s)* with ineligible companies**.
* A “financial relationship" includes employee, researcher (named as the PI), consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and/or an ownership interest (not including stocks owned in a managed portfolio).
** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Bibliographic Resources
• Kidorf M, Disney ER, King VL, Neufeld K, Beilenson PL, Brooner RK. Prevalence of psychiatric and substance use disorders in opioid abusers in a community syringe exchange program. Drug Alcohol Depend. 2004 May 10;74(2):115-22.
• Clark MR, Stoller KB, Brooner RK. Assessment and management of chronic pain in individuals seeking treatment for opioid dependence disorder. Can J Psychiatry. 2008 Aug;53(8):496-508.
• Rosenblum A, Joseph H, Fong C, Kipnis S, Cleland C, Portenoy RK. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA. 2003 May 14;289(18):2370-8.
• Peles E, Schreiber S, Gordon J, Adelson M. Significantly higher methadone dose for methadone maintenance treatment (MMT) patients with chronic pain. Pain. 2005 Feb;113(3):340-346.
• Potter JS, Shiffman SJ, Weiss RD. Chronic pain severity in opioid-dependent patients. Am J Drug Alcohol Abuse. 2008;34(1):101-7.
• Sheu R, Lussier D, Rosenblum A, Fong C, Portenoy J, Joseph H, Portenoy RK. Prevalence and characteristics of chronic pain in patients admitted to an outpatient drug and alcohol treatment program. Pain Med. 2008 Oct;9(7):911-7.
• Harm Reduction Coalition website. Set of principles at: https://harmreduction.org/about-us/principles-of-harm-reduction/
• Providers Clinical Support System (SAMHSA-funded program): https://pcssnow.org/mentoring/
• Federal Guidelines for Opioid Treatment Programs: http://store.samhsa.gov/product/Federal-Guidelines-for-Opioid-Treatment- Programs/PEP15-FEDGUIDEOTP
• SAMHSA TIP 63: Medications for Opioid Use Disorder: https://store.samhsa.gov/product/TIP-63-Medications-for-Opioid-Use- Disorder-Full-Document/PEP21-02-01-002
